Physician profile
James Jay Gordon
NPI 1144239559
$949.90
in general payments reported to CMS, 2019-2025
15 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $17.71 · 2022: $298 · 2023: $171 · 2024: $215 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $259.40 | 2022-2024 | Cuvitru |
| Merck Sharp & Dohme LLC | $162.59 | 2022-2023 | Zerbaxa, Dificid |
| Abbvie INC. | $147.56 | 2023-2025 | |
| Insmed, INC. | $98.89 | 2021-2023 | Arikayce |
| Ferring Pharmaceuticals INC. | $61.92 | 2024-2025 | Rebyota |
| Pfizer INC. | $48.78 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $40.45 | 2024-2025 | Nuzyra |
| Chiesi USA, INC. | $21.49 | 2025 | Cleviprex |
| Glaxosmithkline, LLC. | $17.75 | 2019 | |
| Hospira, INC. | $17.42 | 2024 | |
| Gilead Sciences, INC. | $17.30 | 2019 | |
| Melinta Therapeutics, LLC | $15.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.74 | 2019 | |
| Novo Nordisk INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.